EBV-related PTLD developing after HSCT is a potentially life-threatening disease.
| INTRODUC TI ON
EBV-related PTLD developing after HSCT is a rare life-threatening event.
1 PTLDs are heterogenous lymphoid disorders derived from the proliferation of lymphocytes in the immunocompromised transplant recipient and classified into six main histological categories: plasmacytic hyperplasia, infectious mononucleosis, florid follicular hyperplasia, polymorphic, monomorphic, and classical Hodgkin lymphoma PTLD.
2
Risk factors for development of PTLD include T-cell depletion, mismatched or unrelated donor grafts combined, CB transplant, donor/recipient EBV status, RIC, GVHD, and primary immunodeficiency diseases. 3, 4 Almost 80% of PTLDs are EBV-positive, 4 particularly when the disease occurs early post-transplant 5 which reflects the inability of the new recipient immune system to control EBV-infected B-cell proliferation. 6 It is a standard practice in most pediatric transplant units to closely follow recipient EBV status by monitoring EBV in the blood using PCR, and preemptive treatment strategies to prevent PTLD are being more widely implemented. 7, 8 PTLD seems to be rare after allogeneic HSCT using post-transplant cyclophosphamide as GVHD prophylaxis in adults.
9
HLH is a potentially fatal hyperinflammatory condition.
Secondary HLH may be triggered by a number of disorders including severe infections, malignancy, and rheumatologic conditions. 10, 11 HLH is uncommon after allogeneic HSCT and is mostly associated with infections, especially EBV. 12 Data on outcome of patients with PTLD and concomitant HLH after allogeneic HSCT are limited.
The aim of this study is to determine the incidence of PTLD as well as the outcome of patients who experience PTLD associated with HLH after allogeneic HSCT at The Hospital for Sick Children, Toronto, from 2006 to 2015.
| PATIENTS AND ME THODS
In a retrospective single-institution study, medical charts of all patients who underwent allogeneic HSCT and developed PTLD between 2006 and 2015 at The Hospital for Sick Children in Toronto were reviewed.
Clinical, demographic, laboratory, and outcome data including EBV blood viral load, clinical features, and treatment of EBV disease, as well as HLH manifestations 13 and treatment, were assessed. The study was approved by the hospital research ethics board.
Weekly viral blood monitoring by PCR included CMV, EBV, and HHV6. Supportive care to prevent viral infections for HSV-seropositive patients included acyclovir prophylaxis until engraftment.
CMV-seropositive patients or those with CMV-seropositive donors received CMV prophylaxis with acyclovir from day 0 to day 100.
IVIG was given to keep total IgG level >4 g/L until day +100. HLH diagnosis followed consensus criteria of the Histiocyte Society. 
| Data analysis
Descriptive statistics were used to analyze data, including calculation of the median and range for continuous variables, and underwent PET/CT scan with findings consistent with the diagnosis of PTLD.
| EBV-PTLD post-HSCT
The median time to first positive blood EBV PCR test result post-HSCT was 67 days (range 24-261) (Figure 1 ), and the median days from EBV positivity to start of therapy was 31 days (range 9-106);
neither the time to first EBV positivity nor the time to the start of treatment predicted patients' outcome. An EBV copy number in blood higher that 1 × 10 6 was associated with higher EBV-PTLDrelated mortality (P = 0.047). All of the patients who developed PTLD had ATG as part of the conditioning regimen (P = 0.055).
| Treatment modalities
Treatment modalities of PTLD included weaning of immunosuppressive medications in all patients, rituximab (n = 6), chemotherapy (n = 3), DLIs (n = 2), EBV-CTL (n = 1), and antiviral treatment (n = 6).
Seven patients received combinations of treatment modalities, 
| Mortality from PTLD
Three out of eight patients died secondary to PTLD with survival rate of 62.5% ( Figure 2 ). Two out of three deceased patients had monomorphic PTLD (Burkitt lymphoma, n = 1; diffuse large B-cell lymphoma, n = 1), and the other patients had polymorphic disease.
Death occurred within 1 month of EBV-PTLD diagnosis (range 10-32 days).
| EBV-PTLD-associated HLH
All three deceased patients developed HLH manifestations. Two out of three patients met HLH diagnostic criteria, and one patient had evidence of three criteria with incomplete HLH workup; none of the patients without evidence of HLH died (P = 0.02).
The first patient (P1) was admitted with fever on day +65 post- 
| D ISCUSS I ON
Our study demonstrated that HLH is an indicator of poor outcome in patients with PTLD post-HSCT. In our PTLD cohort, only the three patients who developed manifestations of HLH died of disease (P = 0.02).
The incidence of PTLD in our cohort was 2%, consistent with the previous literature. [15] [16] [17] [18] In a recent large European multicenter study by Styczynski et al F I G U R E 2 Survival rate for patient with PTLD post-HSCT which the highest incidence of PTLD was observed between 1 and 5 months post-transplant followed by a rapid decline.
15,20
In our cohort, all of the patients who developed PTLD had ATG as part of the conditioning regimen (P = 0.055). This is in line with other studies in which ATG was identified as an important risk factor for PTLD as T-cell depletion allows proliferation and infiltration of EBV-infected B cells of different organs.
21-23
Compared to other stem cell sources, PBSC was significantly associated with higher risk of developing EBV-PTLD in our cohort (P = 0.022). This may be explained by the higher number of CD34+ cells in PBSC grafts, which was reported to be associated with a higher risk of EBV reactivation 24 either because of the higher number of EBV-infected B cells in the graft, or stimulation of EBV-infected B-cell proliferation by the cytokines produced by the rapidly maturing myeloid progenitors in the PBSC grafts. 24, 25 The overall survival of patients who developed PTLD in our cohort In contrast to a recent report by Kinch who studied a mixed adult and pediatric cohort (19% children), 4 higher maximum EBV titer in patients with PTLD in our cohort was associated with worse outcome (P = 0.047). This may be explained by differences in age groups and in T-cell recovery, which is considered as an important determinant of disease outcome.
27
Therapy varied among patients. Reduction in immunosuppression to augment T-cell function was the first intervention. In our cohort, one patient with early lesion EBV-PTLD experienced remission with this strategy without the need for further treatment.
With reduction in immunosuppression, remission was observed in 20%-80% of patients in previous reports 28, 29 and the extent of response was dependent on the degree of immunosuppression reduction and the time elapsed since diagnosis. 23 Rituximab is usually administered if no satisfactory response is achieved. In our cohort, three out of six patients (50%) responded to rituximab therapy with different combinations of treatment modalities. Several studies showed a response rate of 40%-68%. 4, [30] [31] [32] Other therapies are based on the clinical situation. Chemotherapy was initiated in patients who were refractory to initial therapy.
Our study identified HLH as an indicator of worse outcome in children with HSCT-PTLD. HLH is fatal if untreated in familial forms. 10 EBV is the major triggering factor in infection-associated secondary HLH especially in the Far East 33 and has a wide range of outcomes. Severe cases have been associated with an underlying immunodeficiency.
34,35
Whereas most of infection-related secondary HLH respond to steroids and treatment of the primary cause, EBV-related HLH is difficult to respond to the same strategy. There are several limitations in our study including small sample size, the retrospective nature of the study, and the lack of a uniform protocol for treatment of patients with EBV-PTLD post-transplant. 
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